List of works - Jan Scicinski

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

scientific article

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

scientific article published on 26 May 2016

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

scientific article

Analysis of Solid-Phase Reactions: Product Identification and Quantification by Use of UV-Chromophore-Containing Dual-Linker Analytical Constructs We thank Dr. P. Marshall for the provision of analytical data.

scientific article

Analytical construct resins for analysis of solid-phase chemistry

scientific article

Analytical techniques for small molecule solid phase synthesis

scientific article

Application of ReactArray Robotics and Design of Experiments Techniques in Optimisation of Supported Reagent Chemistry

article

Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review

scientific article

Clean synthesis of α-bromo ketones and their utilisation in the synthesis of 2-alkoxy-2,3-dihydro-2-aryl-1,4-benzodioxanes, 2-amino-4-aryl-1,3-thiazoles and piperidino-2-amino-1,3-thiazoles using polymer-supported reagents

article published in 1999

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

scientific article published on 13 January 2016

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

scientific article

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

scientific article published on 19 September 2016

Development and Application of a Carbonyl-13C-Enriched Backbone Amide Linker for Solid-Phase Reaction Monitoring

article

Development of an indole safety-catch linker using analytical constructs

scientific article

Development of methods for the bioanalysis of RRx-001 and metabolites.

scientific article published in April 2014

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides

scientific article published on March 1998

Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials

scientific article published on May 2012

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity

scientific article published on 9 December 2015

Episensitization: Defying Time's Arrow

scientific article published on 11 June 2015

Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.

scientific article

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

scientific article

Follow the ATP: tumor energy production: a perspective

scientific article published on January 2014

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria

scientific article published on 28 May 2015

Going viral: a review of replication-selective oncolytic adenoviruses

scientific article (publication date: 21 August 2015)

Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives

scientific article (publication date: 20 May 2002)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

scientific article published on January 2016

Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock

scientific article

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.

scientific article published on April 2012

Light-fluorous safety-catch arylgermanes - exceptionally robust, photochemically activated precursors for biaryl synthesis by Pd(0) catalysed cross-coupling

scientific article published on 21 June 2007

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors

scientific article published on 12 June 2017

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

scientific article published on 22 January 2016

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001

scientific article

No patient left behind: The promise of immune priming with epigenetic agents

scientific article published on 30 August 2017

Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy

scientific article published on 13 April 2014

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

scientific article published on 4 June 2015

Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculation.

scientific article published on 30 March 2012

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

scientific article published on 24 May 2016

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

scientific article published on 28 January 2016

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

scientific article published on 24 April 2016

Preclinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics

scientific article published in April 2006

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent

scientific article published on 14 June 2012

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

scientific article published on January 2016

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

scientific article published on January 2016

RRx-001, A novel dinitroazetidine radiosensitizer

scientific article

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells

scientific article

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors

scientific article published on 11 May 2016

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

scientific article published on 15 January 2016

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

scientific article published on 9 December 2016

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm

scientific article

Rewriting the epigenetic code for tumor resensitization: a review.

scientific article

Rockets, radiosensitizers, and RRx-001: an origin story part I.

scientific article published on March 2016

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

scientific article published on 19 August 2015

Schwesinger Base, Polymer-supported

Single bead characterization using analytical constructs: application to quality control of libraries

scientific article published in March 2001

Six degrees of separation: the oxygen effect in the development of radiosensitizers.

scientific article

Solid-phase development of a L-hydroxybenzotriazole linker for heterocycle synthesis using analytical constructs

scientific article published in July 2001

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

scientific article published on 4 July 2016

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

scientific article published on 27 January 2016

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

scientific article published in August 2015

The Touchstone Process: an ongoing critical evaluation of reiki in the scientific literature

scientific article published on September 2010

The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions

scientific article

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

scientific article published on 19 January 2017

The implications of hyponitroxia in cancer

scientific article published on 04 March 2014

The scarlet letter of alkylation: a mini review of selective alkylating agents.

scientific article published on August 2012

The solid phase synthesis of a series of tri-substituted hydantoin ligands for the somatostatin SST5 receptor

scientific article published on 01 December 1998

The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors

scientific article published on 01 January 1996

The war on cancer: a military perspective

scientific article

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

scientific article

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients

scientific article published on 24 January 2014

Versatile solid-phase synthesis of secondary amines from alcohols. Development of an N-Boc-(o-nitrobenzene)sulfonamide linker

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial

scientific article published on April 2016

List of works by Jan Scicinski

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

Analysis of Solid-Phase Reactions: Product Identification and Quantification by Use of UV-Chromophore-Containing Dual-Linker Analytical Constructs We thank Dr. P. Marshall for the provision of analytical data.

Analytical construct resins for analysis of solid-phase chemistry

Analytical techniques for small molecule solid phase synthesis

Application of ReactArray Robotics and Design of Experiments Techniques in Optimisation of Supported Reagent Chemistry

Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review

Clean synthesis of α-bromo ketones and their utilisation in the synthesis of 2-alkoxy-2,3-dihydro-2-aryl-1,4-benzodioxanes, 2-amino-4-aryl-1,3-thiazoles and piperidino-2-amino-1,3-thiazoles using polymer-supported reagents

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Development and Application of a Carbonyl-13C-Enriched Backbone Amide Linker for Solid-Phase Reaction Monitoring

Development of an indole safety-catch linker using analytical constructs

Development of methods for the bioanalysis of RRx-001 and metabolites.

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides

Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity

Episensitization: Defying Time's Arrow

Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Follow the ATP: tumor energy production: a perspective

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria

Going viral: a review of replication-selective oncolytic adenoviruses

Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.

Light-fluorous safety-catch arylgermanes - exceptionally robust, photochemically activated precursors for biaryl synthesis by Pd(0) catalysed cross-coupling

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001

No patient left behind: The promise of immune priming with epigenetic agents

Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

Oral coadministration of β-glucuronidase to increase exposure of extensively glucuronidated drugs that undergo enterohepatic recirculation.

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Preclinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001, A novel dinitroazetidine radiosensitizer

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm

Rewriting the epigenetic code for tumor resensitization: a review.

Rockets, radiosensitizers, and RRx-001: an origin story part I.

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Schwesinger Base, Polymer-supported

Single bead characterization using analytical constructs: application to quality control of libraries

Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Solid-phase development of a L-hydroxybenzotriazole linker for heterocycle synthesis using analytical constructs

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

The Touchstone Process: an ongoing critical evaluation of reiki in the scientific literature

The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

The implications of hyponitroxia in cancer

The scarlet letter of alkylation: a mini review of selective alkylating agents.

The solid phase synthesis of a series of tri-substituted hydantoin ligands for the somatostatin SST5 receptor

The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors

The war on cancer: a military perspective

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients

Versatile solid-phase synthesis of secondary amines from alcohols. Development of an N-Boc-(o-nitrobenzene)sulfonamide linker

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial